Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update Successfully completed initial public offering, raising $71.4 million in gross proceedsPresented data on AXA1665 and AXA1125 at two leading medical conferencesIdentified drug development path for...

Axcella Health Announces Closing of Initial Public Offering CAMBRIDGE, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated...

Axcella Health Announces Pricing of Initial Public Offering CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated...